Stanozolol

DHT derivative — does not aromatize to estrogen, making it unique among anabolics. Binds androgen receptors with high affinity. Increases SHBG (sex hormone binding globulin) suppression, potentially increasing free testosterone. 17-alpha alkylation allows oral bioavailability but causes hepatotoxicity.

Stanozolol is available in two forms — oral tablets (17-alpha alkylated) and injectable aqueous suspension (also 17-alpha alkylated, unique among injectables). The injectable form is also hepatotoxic unlike most injectable steroids. No traditional ester is used — water suspension for injection.

Stanozolol is a contest prep and strength sport compound. It does not aromatize, does not add water, and produces a harder drier appearance that is specifically valued in the final weeks before competition. Bodybuilders use it during the last four to six weeks of prep when the goal shifts from building to revealing. Powerlifters and strength athletes have used it for the strength increases it produces relative to body weight gain, which matters in weight-class sports. It also has a reputation for increasing vascularity and improving muscle density visually, which is why it appears so consistently in pre-competition protocols across multiple sports.

Stanozolol is a finishing compound, not a base. It does not run alone and it does not run for extended periods. It is added to an existing protocol in the final weeks. In contest prep it typically appears alongside Testosterone Propionate or Masteron Propionate at the tail end of prep when water management is the priority. In strength sport protocols it is sometimes added to a testosterone base during a peaking phase. It is rarely combined with other hepatotoxic orals because the combined liver stress is not manageable over any meaningful duration.

• Hereditary angioedema — primary medical use, still used clinically
• Aplastic anemia
• Vascular disorders — improvement of venous insufficiency
• Veterinary use in horses for muscle preservation and recovery

• Hepatotoxicity — both oral and injectable forms are liver toxic
• Severe HDL suppression — among the most pronounced of any anabolic
• Joint pain — reduction of synovial fluid reported
• Androgenic effects — hair loss, acne in susceptible individuals
• HPTA suppression
• Tendon brittleness reported with prolonged use
• Virilization in women
• Peliosis hepatis with chronic use

The hepatotoxicity of oral Stanozolol is real and the injectable form is equally hepatotoxic, which is unusual among injectables and consistently surprises users who assume injection bypasses liver stress. HDL cholesterol suppression with Stanozolol is among the most severe of any anabolic compound. Users who run it for extended periods or at higher doses are doing measurable cardiovascular damage with every week of use. Joint pain is a frequently reported side effect because the compound reduces synovial fluid, which creates a dry grinding feeling in joints that is the opposite of what Nandrolone produces. The combination of joint pain and the strength increases that make people train heavier creates a mechanical injury risk that is higher than with most other compounds.

Stanozolol metabolites are detectable in urine for 2-3 months. Injectable stanozolol may have slightly shorter detection window than oral form.